FDA update positive for near-term Hologic results, says Barclays

The FDA yesterday afternoon published its June update on industry mammography trends, which included “solid” 3D placements of 121, Barclays analyst Jack Meehan tells investors in a research note. The analyst believes the data are encouraging for near-term results for Hologic in the Breast Health segment. It also helps to show the sustainability of the “tomo tail” with Hologic approaching 60% conversion of its installed base, Meehan contends. He keeps an Overweight rating on Hologic with a $50 price target

https://bit.ly/2IOXQOh